Ruth Gjerset's
Selected PubMed References

Huang Y, Peters CJ, Fitzgerald RC, Gjerset RA
Progressive silencing of p14ARF in esophageal adenocarcinoma.
J Cell Mol Med 2007 in press

Bandyopadhyay K, Lee C, Haghighi A, Banères JL, Parello J, Gjerset RA.
Serine phosphorylation-dependent coregulation of topoisomerase I by the p14ARF tumor suppressor.
Biochemistry. 2007 Dec 11;46(49):14325-34. Epub 2007 Nov 16.

Huang Y, Lee C, Borgström P, Gjerset RA.
Macrophage-mediated bystander effect triggered by tumor cell apoptosis.
Mol Ther. 2007 Mar;15(3):524-33. Epub 2007 Jan 16.

Gjerset RA.
DNA damage, p14ARF, nucleophosmin (NPM/B23), and cancer.
J Mol Histol. 2006 Sep;37(5-7):239-51. Epub 2006 Jul 20. Review.

Gjerset RA, Bandyopadhyay K.
Regulation of p14ARF through subnuclear compartmentalization.
Cell Cycle. 2006 Apr;5(7):686-90. Epub 2006 Apr 1.

Lee C, Smith BA, Bandyopadhyay K, Gjerset RA.
DNA damage disrupts the p14ARF-B23(nucleophosmin) interaction and triggers a transient subnuclear redistribution of p14ARF.
Cancer Res. 2005 Nov 1;65(21):9834-42.

Huang Y, Tyler T, Saadatmandi N, Lee C, Borgstrom P, Gjerset RA.
Enhanced tumor suppression by a p14ARF/p53 bicistronic adenovirus through increased p53 protein translation and stability.
Cancer Res. 2003 Jul 1;63(13):3646-53.

Saadatmandi N, Tyler T, Huang Y, Haghighi A, Frost G, Borgstrom P, Gjerset RA.
Growth Suppression by a p14arf exon 1ß adenovirus in human tumor cell lines of varying p53 and Rb status.
Cancer Gene Ther. 2002 Oct;9(10):830-9.

Lebedeva S, Bagdasarova S, Tyler T, Mu X, Wilson DR, Gjerset RA.
Tumor suppression and therapy sensitization of localized and metastatic breast cancer by adenovirus p53.
Hum Gene Ther. 2001 May 1;12(7):763-72.

Gjerset R, Haghighi A, Lebedeva S, Mercola D.
Gene therapy approaches to sensitization of human prostate carcinoma to cisplatin by adenoviral expression of p53 and by antisense jun kinase oligonucleotide methods.
Methods Mol Biol 2001;175:495-520.

Gjerset RA, Mercola D.
Sensitization of tumors to chemotherapythrough gene therapy.
Adv Exp Med Biol 2000;465:273-91.

Haghighi A, Lebedeva S, Gjerset RA.
Preferential platination of an activated cellular promoter by cis-diamminedichloroplatinum.
Biochemistry. 1999 Sep 21;38(38):12432-8.

Gjerset RA, Lebedeva S, Haghighi A, Turla ST, Mercola D.
Inhibition of the Jun kinase pathway blocks DNA repair, enhances p53-mediated apoptosis and promotes gene amplification.
Cell Growth Differ. 1999 Aug;10(8):545-54.

Dorigo O, Turla ST, Lebedeva S, Gjerset RA.
Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function.
J Neurosurg. 1998 Mar;88(3):535-40.

Fakhrai H, Shawler DL, Van Beveren C, Lin H, Dorigo O, Solomon MJ, Gjerset RA, Smith L, Bartholomew RM, Boggiano CA, Gold DP, Sobol RE.
Construction and characterization of retroviral vectors for interleukin-2 gene therapy.
J Immunother. 1997 Nov;20(6):437-48.

Potapova O, Haghighi A, Bost F, Liu C, Birrer MJ, Gjerset R, Mercola D.
The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin.
J Biol Chem. 1997 May 30;272(22):14041-4.

Gjerset RA, Turla ST, Sobol RE, Scalise JJ, Mercola D, Collins H, Hopkins PJ.
Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53.
Mol Carcinog. 1995 Dec;14(4):275-85.

Shawler DL, Dorigo O, Gjerset RA, Royston I, Sobol RE, Fakhrai H.
Comparison of gene therapy with interleukin-2 gene modified fibroblasts and tumor cells in the murine CT-26 model of colorectal carcinoma.
J Immunother Emphasis Tumor Immunol. 1995 May;17(4):201-8.

Fakhrai H, Shawler DL, Gjerset R, Naviaux RK, Koziol J, Royston I, Sobol RE.
Cytokine gene therapy with interleukin-2-transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity.
Hum Gene Ther. 1995 May;6(5):591-601.

Gjerset RA, Fakhrai H, Shawler DL, Turla S, Dorigo O, Grover-Bardwick A, Mercola D, Wen SF, Collins H, Lin H, et al.
Characterization of a new human glioblastoma cell line that expresses mutant p53 and lacks activation of the PDGF pathway.
In Vitro Cell Dev Biol Anim. 1995 Mar;31(3):207-14.

Sobol RE, Fakhrai H, Shawler D, Gjerset R, Dorigo O, Carson C, Khaleghi T, Koziol J, Shiftan TA, Royston I.
Interleukin-2 gene therapy in a patient with glioblastoma.
Gene Ther. 1995 Mar;2(2):164-7.

Sobol RE, Royston I, Fakhrai H, Shawler DL, Carson C, Dorigo O, Gjerset R, Gold DP, Koziol J, Mercola D, et al.
Injection of colon carcinoma patients with autologous irradiated tumor cells and fibroblasts genetically modified to secrete interleukin-2 (IL-2): a phase I study.
Hum Gene Ther. 1995 Feb;6(2):195-204. No abstract available.

Yeargin J, Cheng J, Yu AL, Gjerset R, Bogart M, Haas M.
P53 mutation in acute T cell lymphoblastic leukemia is of somatic origin and is stable during establishment of T cell acute lymphoblastic leukemia cell lines.
J Clin Invest. 1993 May;91(5):2111-7.

Feldman ST, Gjerset R, Gately D, Chien KR, Feramisco JR.
Expression of SV40 virus large T antigen by recombinant adenoviruses activates proliferation of corneal endothelium in vitro.
J Clin Invest. 1993 Apr;91(4):1713-20.